Amgen Inc (AMGN) 169.77 $AMGN Gilead Gets Wall
Post# of 273330
Posted On: 07/29/2015 1:24:42 PM
Amgen Inc (AMGN) 169.77 $AMGN
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - 55 mins ago
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 116.51 (+3.44), AMGN: 169.77 (-2.97), ABBV: 71.32 (+0.09), CELG: 132.92 (-2.50)
Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - 1 hr 36 mins ago
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 310.43 (-9.50), VRTX: 127.11 (-1.19), ALXN: 202.14 (-1.41), AMGN: 169.77 (-2.97), ABBV: 71.32 (+0.09), REGN: 541.95 (-10.50), XOMA: 0.83 (-0.05)
Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 310.43 (-9.50), F: 15.08 (+0.25), RIG: 14.48 (+0.36), GILD: 116.50 (+3.43), PFE: 35.71 (+0.36), COP: 53.05 (+0.81), XOM: 82.95 (+0.47), AMGN: 169.77 (-2.97), DD: 55.69 (-0.21), CVX: 93.05 (+0.65), SLB: 83.86 (+1.36), UPS: 100.73 (+0.79), CELG: 132.92 (-2.50)
Critical Alerts For Seadrill, Amgen, Ariad Pharmaceuticals, Johnson Controls and ACADIA Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, AMGN, ARIA, JCI and ACAD.
ACAD: 48.19 (-1.11), AMGN: 169.77 (-2.97), ARIA: 7.75 (-0.47), SDRL: 9.74 (+0.76), JCI: 45.05 (+0.61)
Amgen to pay USD0.79 per share dividend in Q3 2015
M2 - Wed Jul 29, 3:58AM CDT
The board of directors of Amgen (NasdaqGS:AMGN) on Tuesday declared a dividend of USD0.79 per share for the third quarter of 2015.
AMGN: 169.77 (-2.97)
Global Biosimilars Market 2015 - 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others
M2 - Wed Jul 29, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nznw98/global) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" report to their offering. The Global Biosimilars Market, 2015 - 2025' report provides an extensive study of the rapidly growing biosimilars market. With the blockbuster biologics losing patent protection and biotechnology industry striving to minimize costs, biosimilars are being viewed as viable substitutes to the highly expensive biological medications. The study presents an in-depth review of the developments in established markets and emerging regions, with respect to the market landscape, global and local players, regulatory scenario and emerging opportunities. It provides a detailed analysis of the worldwide pipeline of biosimilars on key parameters such as product categories, indications, biosimilar targets and status of development. The study presents a comprehensive view of key product classes into which biosimilars can be categorized; these include monoclonal antibodies (mAbs), insulin, interferons, G-CSF/ GM-CSF, erythropoietins and others. We have highlighted some of the important aspects specific to these product categories including regulatory guidelines, development challenges, marketed / pipeline biosimilars, sales data (where available) and information on patent expiry of the reference products. The report assesses some of the key drivers that have governed the evolution of biosimilars market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity in the biosimilars market over the next decade, segmented on the basis of geographical clusters and product categories. The study also provides information on some of the most recent activities in this market; amongst others, these include growing collaborations, investment activity and technological advancements. In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples of such challenges include manufacturing complexities, heterogeneous regulatory framework, and associated safety and efficacy issues. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run. The report provides market forecasts for the time period 2020 and 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Biosimilars: Developed Markets 5. Biosimilars: Emerging Markets 6. Global Market Overview 7. Market Dynamics 8. Monoclonal Antibody Biosimilars 9. Insulin Biosimilars 10. Biosimilar Interferons 11. Other Leading Biosimilar Markets 12. Recent Developments 13. Outsourcing of Biosimilars 14. Market Forecast 15. Conclusion 16. Interview Transcripts 17. Appendix 1: Tabulated Data 18. Appendix 2: List of Companies and Organisations Companies Mentioned - 35 of the 300 Companies Featured - 3S Bio Inc. - Abbott - AbZ Pharma - Accord Healthcare Ltd. - Actavis - Aequus BioPharma - AET Biotech - Agila Biotech - Alvartis Pharma - Alvogen - Amega Biotech - Amgen - Anhui Anke Biotechnology (Group) Co., Ltd - Anika Therapeutics - ANMAT (Argentina) - Apotex - Aprogen Inc. - AryoGen - ASKA Pharmaceutical Co. Ltd. - Aspen Pharmacare Australia - Avesthagen - Axicorp GmbH - AXXO GmbH - Barr Pharmaceuticals - Baxter International - Bayer Healthcare - Beacon Pharmaceuticals Ltd. - Beijing Four Rings Bio-Pharmaceutical - Beijing ShuangLu Pharmaceutical Co., Ltd. - Bharat Serums - Binex - Bio Process - Bio Profarma SA - Bio Sidus SA - Biocad For more information visit http://www.researchandmarkets.com/research/nznw98/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BAX: 38.41 (+0.32), AMGN: 169.77 (-2.97), ANIK: 34.64 (-0.75)
Amgen Announces 2015 Third Quarter Dividend
PR Newswire - Tue Jul 28, 4:46PM CDT
Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.79 per share dividend for the third quarter of 2015. The dividend will be paid on Sept. 8, 2015, to all stockholders of record as of the close of business on Aug. 17, 2015.
AMGN: 169.77 (-2.97)
Amgen Set to Possibly Pullback After Yesterday's Rally of 4.35%
Comtex SmarTrend(R) - Tue Jul 28, 4:28PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $166.12 to a high of $174.80. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $165.94 on volume of 8.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 169.77 (-2.97)
After Yesterday's Rally of 4.35% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jul 28, 4:27PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $166.12 to a high of $174.80. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $165.94 on volume of 8.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 169.77 (-2.97)
Will Amgen (AMGN) Keep the Earnings Streak Alive in 2Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 28, 3:25PM CDT
Amgen's (AMGN) track record is pretty impressive with the company beating earnings estimates consistently.
MNK: 123.41 (-0.46), BMRN: 142.68 (-3.26), MDCO: 31.90 (-1.58), AMGN: 169.77 (-2.97)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 336.81 (-2.69), BIIB: 310.43 (-9.50), SHPG: 264.98 (+1.73), MYL: 56.98 (+0.63), AMGN: 169.77 (-2.97), ABBV: 71.32 (+0.09), TEVA: 70.95 (-0.46)
NantKwest Surges As Biggest Biotech Market Cap IPO
at Investor's Business Daily - Tue Jul 28, 11:08AM CDT
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 70.29 (-1.62), NK: 35.08 (+0.44), ALXN: 202.14 (-1.41), RCPT: 227.87 (+0.71), AMGN: 169.77 (-2.97), JUNO: 48.03 (-0.59), CELG: 132.92 (-2.50)
Merck Tops on Q2 Earnings & Revenues, Revises Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 28, 9:43AM CDT
Merck (MRK) narrowed and raised its earnings guidance for 2015.
ABT: 50.94 (unch), MRK: 58.58 (+1.06), AMGN: 169.77 (-2.97), LLY: 84.99 (-0.69)
Next Resistance Level for Amgen (AMGN) is $170.33
Comtex SmarTrend(R) - Tue Jul 28, 9:31AM CDT
Shares of Amgen (NASDAQ:AMGN) opened today above their pivot of $163.55 and have already reached the first level of resistance at $167.93. Analysts will be watching for a cross of the next upside pivot targets of $170.33 and $177.11.
AMGN: 169.77 (-2.97)
Gliosarcoma Pipeline Review H1 2015 - Analysis of 7 Companies & 11 Drug Profiles
M2 - Tue Jul 28, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mmkt6/gliosarcoma) has announced the addition of the "Gliosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Burzynski Research Institute, Inc. - Celgene Corporation - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Sanofi Drug Profiles - alisertib - Antineoplaston Therapy - CC-122 - DNX-2401 - indoximod - lonafarnib - Oncolytic Virus to Target IL-12 for Oncology - plerixafor - rilotumumab - SGT-53 - Stem Cell Therapy for Glioma For more information visit http://www.researchandmarkets.com/research/5m...liosarcoma
MRK: 58.58 (+1.06), NLNK: 51.26 (-2.55), AMGN: 169.77 (-2.97), CELGZ: 2.07 (+0.03)
3 Questions to Ask Ahead of Amgen's Second-Quarter Earnings Release
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 27, 5:26PM CDT
Source: Amgen via Flickr. Things have really come together nicely for biotech blue-chip stock Amgen over the last couple of years. Following a decade where its share price had essentially gone nowhere despite aggressive share buybacks, the...
AMGN: 169.77 (-2.97)
Amgen Announces Webcast of 2015 Second Quarter Financial Results
PR Newswire - Mon Jul 27, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 30, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
AMGN: 169.77 (-2.97)
Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jul 27, 1:56PM CDT
Healthcare giants Regeneron Pharmaceuticals and Sanofi SA (ADR) treated their investors to great news over the weekend as the companies announced that they won FDA approval of their highly anticipated cholesterol-lowering medication Praluent. ...
AMGN: 169.77 (-2.97), SNY: 53.87 (+0.06), REGN: 542.01 (-10.44)
4 Stocks Spiking on Unusual Volume
at The Street - Mon Jul 27, 1:39PM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
SWI: 38.71 (+0.26), ITEK: 16.52 (-0.58), AMGN: 169.77 (-2.97), URI: 66.90 (-0.03)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 156.02 (-4.30), BIIB: 310.43 (-9.50), LGND: 104.25 (-1.59), AMGN: 169.77 (-2.97), REGN: 542.01 (-10.44), EXEL: 5.64 (+0.23), CELG: 132.92 (-2.50)
Gilead Gets Wall Street Love After Q2 Earnings Beat
at Investor's Business Daily - 55 mins ago
Big biotech Gilead Sciences (GILD) got a passel of price target increases and jumped more than 5.5% on the stock market Wednesday in the wake of its stellar Q2 report late Tuesday. Analysts noted the strong sales of hepatitis C virus (HCV) drugs and...
GILD: 116.51 (+3.44), AMGN: 169.77 (-2.97), ABBV: 71.32 (+0.09), CELG: 132.92 (-2.50)
Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA Nod - Analyst Blog
Arpita Dutt - Zacks Investment Research - 1 hr 36 mins ago
Last week saw several major biotech companies like Biogen (BIIB) and AbbVie (ABBV) reporting second quarter results.
BIIB: 310.43 (-9.50), VRTX: 127.11 (-1.19), ALXN: 202.14 (-1.41), AMGN: 169.77 (-2.97), ABBV: 71.32 (+0.09), REGN: 541.95 (-10.50), XOMA: 0.83 (-0.05)
Stock Market News for July 29, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 29, 9:10AM CDT
Benchmarks gained over 1% on Tuesday as investors focused on upbeat earnings results, ignoring the selloff in China’s stock market
BIIB: 310.43 (-9.50), F: 15.08 (+0.25), RIG: 14.48 (+0.36), GILD: 116.50 (+3.43), PFE: 35.71 (+0.36), COP: 53.05 (+0.81), XOM: 82.95 (+0.47), AMGN: 169.77 (-2.97), DD: 55.69 (-0.21), CVX: 93.05 (+0.65), SLB: 83.86 (+1.36), UPS: 100.73 (+0.79), CELG: 132.92 (-2.50)
Critical Alerts For Seadrill, Amgen, Ariad Pharmaceuticals, Johnson Controls and ACADIA Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, AMGN, ARIA, JCI and ACAD.
ACAD: 48.19 (-1.11), AMGN: 169.77 (-2.97), ARIA: 7.75 (-0.47), SDRL: 9.74 (+0.76), JCI: 45.05 (+0.61)
Amgen to pay USD0.79 per share dividend in Q3 2015
M2 - Wed Jul 29, 3:58AM CDT
The board of directors of Amgen (NasdaqGS:AMGN) on Tuesday declared a dividend of USD0.79 per share for the third quarter of 2015.
AMGN: 169.77 (-2.97)
Global Biosimilars Market 2015 - 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others
M2 - Wed Jul 29, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nznw98/global) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" report to their offering. The Global Biosimilars Market, 2015 - 2025' report provides an extensive study of the rapidly growing biosimilars market. With the blockbuster biologics losing patent protection and biotechnology industry striving to minimize costs, biosimilars are being viewed as viable substitutes to the highly expensive biological medications. The study presents an in-depth review of the developments in established markets and emerging regions, with respect to the market landscape, global and local players, regulatory scenario and emerging opportunities. It provides a detailed analysis of the worldwide pipeline of biosimilars on key parameters such as product categories, indications, biosimilar targets and status of development. The study presents a comprehensive view of key product classes into which biosimilars can be categorized; these include monoclonal antibodies (mAbs), insulin, interferons, G-CSF/ GM-CSF, erythropoietins and others. We have highlighted some of the important aspects specific to these product categories including regulatory guidelines, development challenges, marketed / pipeline biosimilars, sales data (where available) and information on patent expiry of the reference products. The report assesses some of the key drivers that have governed the evolution of biosimilars market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity in the biosimilars market over the next decade, segmented on the basis of geographical clusters and product categories. The study also provides information on some of the most recent activities in this market; amongst others, these include growing collaborations, investment activity and technological advancements. In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples of such challenges include manufacturing complexities, heterogeneous regulatory framework, and associated safety and efficacy issues. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run. The report provides market forecasts for the time period 2020 and 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Biosimilars: Developed Markets 5. Biosimilars: Emerging Markets 6. Global Market Overview 7. Market Dynamics 8. Monoclonal Antibody Biosimilars 9. Insulin Biosimilars 10. Biosimilar Interferons 11. Other Leading Biosimilar Markets 12. Recent Developments 13. Outsourcing of Biosimilars 14. Market Forecast 15. Conclusion 16. Interview Transcripts 17. Appendix 1: Tabulated Data 18. Appendix 2: List of Companies and Organisations Companies Mentioned - 35 of the 300 Companies Featured - 3S Bio Inc. - Abbott - AbZ Pharma - Accord Healthcare Ltd. - Actavis - Aequus BioPharma - AET Biotech - Agila Biotech - Alvartis Pharma - Alvogen - Amega Biotech - Amgen - Anhui Anke Biotechnology (Group) Co., Ltd - Anika Therapeutics - ANMAT (Argentina) - Apotex - Aprogen Inc. - AryoGen - ASKA Pharmaceutical Co. Ltd. - Aspen Pharmacare Australia - Avesthagen - Axicorp GmbH - AXXO GmbH - Barr Pharmaceuticals - Baxter International - Bayer Healthcare - Beacon Pharmaceuticals Ltd. - Beijing Four Rings Bio-Pharmaceutical - Beijing ShuangLu Pharmaceutical Co., Ltd. - Bharat Serums - Binex - Bio Process - Bio Profarma SA - Bio Sidus SA - Biocad For more information visit http://www.researchandmarkets.com/research/nznw98/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BAX: 38.41 (+0.32), AMGN: 169.77 (-2.97), ANIK: 34.64 (-0.75)
Amgen Announces 2015 Third Quarter Dividend
PR Newswire - Tue Jul 28, 4:46PM CDT
Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.79 per share dividend for the third quarter of 2015. The dividend will be paid on Sept. 8, 2015, to all stockholders of record as of the close of business on Aug. 17, 2015.
AMGN: 169.77 (-2.97)
Amgen Set to Possibly Pullback After Yesterday's Rally of 4.35%
Comtex SmarTrend(R) - Tue Jul 28, 4:28PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $166.12 to a high of $174.80. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $165.94 on volume of 8.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 169.77 (-2.97)
After Yesterday's Rally of 4.35% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jul 28, 4:27PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $166.12 to a high of $174.80. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $165.94 on volume of 8.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 169.77 (-2.97)
Will Amgen (AMGN) Keep the Earnings Streak Alive in 2Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 28, 3:25PM CDT
Amgen's (AMGN) track record is pretty impressive with the company beating earnings estimates consistently.
MNK: 123.41 (-0.46), BMRN: 142.68 (-3.26), MDCO: 31.90 (-1.58), AMGN: 169.77 (-2.97)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 336.81 (-2.69), BIIB: 310.43 (-9.50), SHPG: 264.98 (+1.73), MYL: 56.98 (+0.63), AMGN: 169.77 (-2.97), ABBV: 71.32 (+0.09), TEVA: 70.95 (-0.46)
NantKwest Surges As Biggest Biotech Market Cap IPO
at Investor's Business Daily - Tue Jul 28, 11:08AM CDT
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 70.29 (-1.62), NK: 35.08 (+0.44), ALXN: 202.14 (-1.41), RCPT: 227.87 (+0.71), AMGN: 169.77 (-2.97), JUNO: 48.03 (-0.59), CELG: 132.92 (-2.50)
Merck Tops on Q2 Earnings & Revenues, Revises Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 28, 9:43AM CDT
Merck (MRK) narrowed and raised its earnings guidance for 2015.
ABT: 50.94 (unch), MRK: 58.58 (+1.06), AMGN: 169.77 (-2.97), LLY: 84.99 (-0.69)
Next Resistance Level for Amgen (AMGN) is $170.33
Comtex SmarTrend(R) - Tue Jul 28, 9:31AM CDT
Shares of Amgen (NASDAQ:AMGN) opened today above their pivot of $163.55 and have already reached the first level of resistance at $167.93. Analysts will be watching for a cross of the next upside pivot targets of $170.33 and $177.11.
AMGN: 169.77 (-2.97)
Gliosarcoma Pipeline Review H1 2015 - Analysis of 7 Companies & 11 Drug Profiles
M2 - Tue Jul 28, 9:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mmkt6/gliosarcoma) has announced the addition of the "Gliosarcoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Burzynski Research Institute, Inc. - Celgene Corporation - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Sanofi Drug Profiles - alisertib - Antineoplaston Therapy - CC-122 - DNX-2401 - indoximod - lonafarnib - Oncolytic Virus to Target IL-12 for Oncology - plerixafor - rilotumumab - SGT-53 - Stem Cell Therapy for Glioma For more information visit http://www.researchandmarkets.com/research/5m...liosarcoma
MRK: 58.58 (+1.06), NLNK: 51.26 (-2.55), AMGN: 169.77 (-2.97), CELGZ: 2.07 (+0.03)
3 Questions to Ask Ahead of Amgen's Second-Quarter Earnings Release
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 27, 5:26PM CDT
Source: Amgen via Flickr. Things have really come together nicely for biotech blue-chip stock Amgen over the last couple of years. Following a decade where its share price had essentially gone nowhere despite aggressive share buybacks, the...
AMGN: 169.77 (-2.97)
Amgen Announces Webcast of 2015 Second Quarter Financial Results
PR Newswire - Mon Jul 27, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, July 30, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
AMGN: 169.77 (-2.97)
Regeneron Pharmaceuticals and Sanofi Grab a Blockbuster FDA Approval
Brian Feroldi, The Motley Fool - Motley Fool - Mon Jul 27, 1:56PM CDT
Healthcare giants Regeneron Pharmaceuticals and Sanofi SA (ADR) treated their investors to great news over the weekend as the companies announced that they won FDA approval of their highly anticipated cholesterol-lowering medication Praluent. ...
AMGN: 169.77 (-2.97), SNY: 53.87 (+0.06), REGN: 542.01 (-10.44)
4 Stocks Spiking on Unusual Volume
at The Street - Mon Jul 27, 1:39PM CDT
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
SWI: 38.71 (+0.26), ITEK: 16.52 (-0.58), AMGN: 169.77 (-2.97), URI: 66.90 (-0.03)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 156.02 (-4.30), BIIB: 310.43 (-9.50), LGND: 104.25 (-1.59), AMGN: 169.77 (-2.97), REGN: 542.01 (-10.44), EXEL: 5.64 (+0.23), CELG: 132.92 (-2.50)
(0)
(0)